LU92853I2 - Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine - Google Patents
Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine Download PDFInfo
- Publication number
- LU92853I2 LU92853I2 LU92853C LU92853C LU92853I2 LU 92853 I2 LU92853 I2 LU 92853I2 LU 92853 C LU92853 C LU 92853C LU 92853 C LU92853 C LU 92853C LU 92853 I2 LU92853 I2 LU 92853I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- rilpivirine
- emtricitabine
- protected
- pharmaceutically acceptable
- combination
- Prior art date
Links
- 229960002814 rilpivirine Drugs 0.000 title 2
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 title 1
- 229960000366 emtricitabine Drugs 0.000 title 1
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical class Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49977103P | 2003-09-03 | 2003-09-03 | |
| EP03103275 | 2003-09-03 | ||
| EP03103319 | 2003-09-08 | ||
| EP03103335 | 2003-09-10 | ||
| EP03103668 | 2003-10-02 | ||
| US50848603P | 2003-10-03 | 2003-10-03 | |
| EP04787096.9A EP1663240B2 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| PCT/EP2004/052028 WO2005021001A1 (en) | 2003-09-03 | 2004-09-03 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92853I2 true LU92853I2 (fr) | 2015-12-21 |
Family
ID=34280181
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92853C LU92853I2 (fr) | 2003-09-03 | 2015-10-20 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine |
| LU92854C LU92854I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil |
| LU92855C LU92855I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92854C LU92854I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil |
| LU92855C LU92855I2 (fr) | 2003-09-03 | 2015-10-21 | Combinaison de rilpivirine ou une forme thérapeutique equivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, ténofovir, en particulier le fumarate de ténofovir disoproxil, et l'emtricitabine |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US20080200435A1 (enExample) |
| EP (1) | EP1663240B2 (enExample) |
| JP (3) | JP5507791B2 (enExample) |
| KR (1) | KR20060090658A (enExample) |
| CN (1) | CN101060844B (enExample) |
| AP (1) | AP2109A (enExample) |
| AU (5) | AU2004268390B2 (enExample) |
| BE (1) | BE2015C053I2 (enExample) |
| CA (1) | CA2537095C (enExample) |
| CY (5) | CY2015038I1 (enExample) |
| FI (1) | FI1663240T4 (enExample) |
| FR (5) | FR15C0073I2 (enExample) |
| HR (1) | HRP20150798T4 (enExample) |
| HU (5) | HUS1500054I1 (enExample) |
| IL (2) | IL173438A (enExample) |
| LT (2) | LTC1663240I2 (enExample) |
| LU (3) | LU92853I2 (enExample) |
| MX (1) | MXPA06002437A (enExample) |
| MY (1) | MY169670A (enExample) |
| NL (2) | NL300781I1 (enExample) |
| NO (6) | NO334877B1 (enExample) |
| NZ (1) | NZ545306A (enExample) |
| PL (1) | PL1663240T5 (enExample) |
| WO (1) | WO2005021001A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
| US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| CA2686429C (en) | 2002-08-09 | 2010-11-16 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| HRP20140379A2 (hr) | 2003-01-14 | 2014-07-18 | Gilead Sciences, Inc. | Pripravci i metode za kombiniranu antivirusnu terapiju |
| BRPI0514861A (pt) * | 2004-09-02 | 2008-06-24 | Janssen Pharmaceutica Nv | furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila |
| UA92467C2 (ru) * | 2004-09-02 | 2010-11-10 | Янссен Фармацевтика Н.В. | Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила |
| BRPI0514871A (pt) * | 2004-09-02 | 2008-06-24 | Janssen Pharmaceutica Nv | cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila |
| KR101284361B1 (ko) * | 2004-09-02 | 2013-07-15 | 얀센 파마슈티카 엔.브이. | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 |
| WO2006024667A1 (en) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
| TWI457136B (zh) * | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| ATE474560T1 (de) * | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| AU2007206901B2 (en) * | 2006-01-20 | 2013-01-31 | Janssen Sciences Ireland Uc | Long term treatment of HIV- infection with TCM278 |
| US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
| FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
| AR065720A1 (es) * | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| WO2009115652A2 (fr) * | 2008-01-03 | 2009-09-24 | Universite De La Mediterannee, Aix-Marseille Ii | Composition et procedes utilisables lors d'un traitement anti-vih |
| NZ593950A (en) * | 2008-12-24 | 2013-08-30 | Janssen R & D Ireland | Implantable devices for treating hiv |
| ES2600878T3 (es) | 2009-12-21 | 2017-02-13 | Janssen Sciences Ireland Uc | Implante removible, degradable, para la liberación prolongada de un compuesto activo |
| DK2932970T3 (en) | 2010-01-27 | 2018-05-28 | Viiv Healthcare Co | ANTIVIRAL THERAPY |
| KR101923103B1 (ko) * | 2010-11-19 | 2018-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물 |
| WO2012125993A1 (en) | 2011-03-17 | 2012-09-20 | Teva Pharmaceutical Industries Ltd. | Solid state forms of rilpivirine base, and rilipivirine salts |
| EP2755959B1 (en) * | 2011-09-16 | 2018-05-16 | Hetero Research Foundation | Rilpivirine hydrochloride |
| DK2822954T3 (en) | 2012-12-21 | 2016-05-30 | Gilead Sciences Inc | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| BR102016026127A2 (pt) | 2015-11-09 | 2017-05-16 | Gilead Sciences Inc | composições terapêuticas para o tratamento do vírus da imunodeficiência humana |
| FI3528791T3 (fi) | 2016-10-24 | 2024-01-30 | Janssen Sciences Ireland Unlimited Co | Dispergoituvia koostumuksia |
| US20210128554A1 (en) * | 2016-12-23 | 2021-05-06 | Temple University - Of The Commonwealth System Of Higher Education | Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis) |
| WO2018193470A1 (en) * | 2017-04-18 | 2018-10-25 | Cipla Limited | Combination therapy for use in treating retroviral infections |
| WO2019021319A1 (en) * | 2017-07-27 | 2019-01-31 | Cipla Limited | PHARMACEUTICAL COMPOSITIONS |
| AU2020391004A1 (en) | 2019-11-29 | 2022-04-07 | Aptorum Therapeutics Limited | Composition including rilpivirine and use thereof for treating tumors or cancer |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
| MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| EP0489181B1 (en) | 1990-07-19 | 1996-10-02 | Otsuka Pharmaceutical Co., Ltd. | Solid preparation |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JPH07503943A (ja) | 1991-10-29 | 1995-04-27 | クローバー コンソリデイテッド,リミテッド | 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質 |
| AU4079593A (en) | 1992-05-13 | 1993-12-13 | Wellcome Foundation Limited, The | Therapeutic combinations |
| JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
| TW401303B (en) * | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
| IT1281502B1 (it) * | 1995-06-13 | 1998-02-18 | Sardinian Antiviral Research C | Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| IL148685A0 (en) | 1999-09-21 | 2002-09-12 | Rtp Pharma Inc | Surface modified particulate compositions of biologically active substances |
| US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| TW200800298A (en) | 2000-01-27 | 2008-01-01 | Zentaris Ag | Compressed microparticles for dry injection |
| US7135465B2 (en) | 2000-03-30 | 2006-11-14 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
| US20040115268A1 (en) | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
| DE10050199A1 (de) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Flächiges Implantat mit im Ultraschall detektierbaren Elementen |
| CN1487935A (zh) | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 改良型水溶性药物组合物 |
| JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| CA2465779A1 (en) | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
| CA2686429C (en) | 2002-08-09 | 2010-11-16 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| WO2004022033A1 (en) | 2002-09-04 | 2004-03-18 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
| WO2004043433A2 (en) | 2002-11-08 | 2004-05-27 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
| EA009871B1 (ru) | 2002-11-15 | 2008-04-28 | Тиботек Фармасьютикалз Лтд. | Замещённые индолпиридиниевые соединения в качестве противоинфекционного средства |
| AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| HRP20050688B1 (hr) | 2003-02-07 | 2017-03-24 | Janssen Pharmaceutica N.V. | Derivati pirimidina za sprječavanje hiv infekcije |
| KR100629771B1 (ko) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| ZA200700030B (en) | 2004-06-08 | 2009-06-24 | Vertex Pharma | Pharmaceutical compositions |
| MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| BRPI0514871A (pt) | 2004-09-02 | 2008-06-24 | Janssen Pharmaceutica Nv | cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila |
| KR101284361B1 (ko) | 2004-09-02 | 2013-07-15 | 얀센 파마슈티카 엔.브이. | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 |
| WO2006055603A2 (en) | 2004-11-16 | 2006-05-26 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
| TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
| CA2603851A1 (en) | 2005-04-11 | 2006-10-19 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Multi-layer structure having a predetermined layer pattern including an agent |
| TW200710091A (en) | 2005-04-11 | 2007-03-16 | Tibotec Pharm Ltd | (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors |
| EP1893180A2 (en) | 2005-06-07 | 2008-03-05 | Pfizer Products Inc. | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
| US20070026073A1 (en) | 2005-07-28 | 2007-02-01 | Doney John A | Amorphous efavirenz and the production thereof |
| AU2007206901B2 (en) | 2006-01-20 | 2013-01-31 | Janssen Sciences Ireland Uc | Long term treatment of HIV- infection with TCM278 |
| CL2007001847A1 (es) | 2006-06-23 | 2008-02-08 | Tibotec Pharm Ltd | Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih. |
| WO2008060360A2 (en) | 2006-09-28 | 2008-05-22 | Surmodics, Inc. | Implantable medical device with apertures for delivery of bioactive agents |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| CA2693044C (en) | 2007-07-12 | 2017-03-14 | Tibotec Pharmaceuticals | Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
| US20090123508A1 (en) | 2007-10-04 | 2009-05-14 | Boston Scientific Scimed, Inc. | Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management |
| WO2010047819A1 (en) | 2008-10-24 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Hydroxyethylamino sulfonamide derivatives |
-
2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en not_active Expired - Lifetime
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en not_active Ceased
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 CA CA2537095A patent/CA2537095C/en not_active Expired - Lifetime
-
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
-
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en not_active Expired - Lifetime
-
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
-
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
-
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I1/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/xx unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/xx unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 CY CY2015038C patent/CY2015038I1/el unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/xx unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I1/el unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
-
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 FR FR16C1024C patent/FR16C1024I1/fr active Active
- 2016-12-20 CY CY2016049C patent/CY2016049I1/el unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 FR FR16C1022C patent/FR16C1022I1/fr active Active
- 2016-12-20 CY CY2016048C patent/CY2016048I1/el unknown
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
-
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
-
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
-
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU92853I2 (fr) | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégée par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine et l'emtricitabine | |
| LU92496I2 (fr) | Combinaison de dapagliflozine ou d'un sel pharmaceutiquement acceptable de celle-ci et de merformineou d'un sel pharmaceutiquement acceptable de cell-ci, telle que protégée par le brevet de base EP1506211 B1 | |
| BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
| BR0308452A (pt) | composições farmacêuticas e métodos de preparação de composição farmacêutica | |
| ATE454138T1 (de) | Tablette mit modifizierter freisetzung von bupropion hydrochlorid | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| EE05107B1 (et) | Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine | |
| MA27372A1 (fr) | Forme posologique de pramipexole à administration une fois par jour | |
| BR0209020A (pt) | Composição farmacêutica de polialilamina | |
| PT1435915E (pt) | Formas de administração oral de propiverina ou de seus sais farmaceuticamente aceitáveis com libertação prolongada da substância activa | |
| EP1450803A4 (en) | NEW USES FOR ANTIMALARIAL THERAPEUTIC AGENTS | |
| MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
| UA90518C2 (ru) | Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин | |
| EP1800693A4 (en) | ADJUVANT THERAPY USING ANTI-GLYPICAN-3 ANTIBODY | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| ATE308522T1 (de) | Opioidrezeptorantagonisten | |
| SE0102440D0 (sv) | New compound | |
| DK1267847T3 (da) | 5HT2-antagonist til regulering af IOP og behandling af glaucom | |
| ATE469642T1 (de) | Vorbeugungs- oder heilmittel gegen endometriose | |
| PL369736A1 (en) | New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors | |
| IL165851A0 (en) | The use of benziselenazolone compounds in the preparation of medicament against ischemic myocardial injury | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| DE60230785D1 (de) | Polymorphe marker die benutzt werden kann, um die wirksamkeit der interferon-therapie festzustellen |